ID   IM-9
AC   CVCL_1305
SY   IM 9; IM9; GM04680
DR   BTO; BTO:0002897
DR   CLO; CLO_0006703
DR   CLO; CLO_0006705
DR   CLO; CLO_0019036
DR   CLDB; cl2635
DR   CLDB; cl2636
DR   CLDB; cl2637
DR   CLDB; cl4962
DR   CLDB; cl5210
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CCL-159
DR   BCRC; 60115
DR   BioGRID_ORCS_Cell_line; 899
DR   BioSample; SAMN03471460
DR   BioSample; SAMN03472807
DR   CCRID; 1102HUM-NIFDC00064
DR   Cell_Model_Passport; SIDM00632
DR   ChEMBL-Cells; CHEMBL3307412
DR   ChEMBL-Targets; CHEMBL614584
DR   CLS; 302151
DR   Coriell; GM04680
DR   Cosmic; 753563
DR   Cosmic; 888021
DR   Cosmic; 919137
DR   Cosmic-CLP; 753563
DR   DepMap; ACH-002247
DR   DSMZ; ACC-117
DR   DSMZCellDive; ACC-117
DR   ECACC; 86051302
DR   EGA; EGAS00001000978
DR   GDSC; 753563
DR   GEO; GSM1374572
DR   GEO; GSM1669932
DR   IARC_TP53; 21395
DR   ICLC; HTL99009
DR   IZSLER; BS TCL 98
DR   JCRB; IFO50025
DR   JCRB; JCRB0024
DR   KCLB; 10159
DR   LINCS_LDP; LCL-1958
DR   Lonza; 9
DR   PharmacoDB; IM9_656_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1305
DR   Wikidata; Q54897504
RX   CelloPub=CLPUB00447;
RX   PubMed=1366653;
RX   PubMed=2836165;
RX   PubMed=7579375;
RX   PubMed=8139288;
RX   PubMed=9290701;
RX   PubMed=9510473;
RX   PubMed=10516762;
RX   PubMed=10936422;
RX   PubMed=20164919;
RX   PubMed=20454443;
RX   PubMed=27397505;
RX   PubMed=29892436;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Problematic cell line: Misclassified. Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=10516762).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~45 hours (DSMZ=ACC-117); ~1 day (Note=Lot 09172008), ~23 hours (Note=Lot 03302009) (JCRB=JCRB0024).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.41%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=68.16%; European, South=31.43% (PubMed=30894373).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; DSMZ; JCRB; KCLB
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 9,11
ST   D16S539: 9,13
ST   D18S51: 14,17
ST   D19S433: 13,14
ST   D21S11: 30,30.2
ST   D2S1338: 24,26
ST   D3S1358: 14,18
ST   D5S818: 13
ST   D7S820: 11,12
ST   D8S1179: 12,13
ST   FGA: 20,23
ST   Penta D: 9,11
ST   Penta E: 13,15
ST   TH01: 6,9.3 (ATCC; CCRID; Cosmic-CLP; DSMZ; KCLB)
ST   TH01: 6,10 (JCRB)
ST   TPOX: 11
ST   vWA: 14,17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
//
RX   PubMed=1366653; DOI=10.1007/BF00365265;
RA   Bonhoff A., Gellersen B., Held K.R., Bohnet H.G.;
RT   "Clonal derivatives of a human B-lymphoblastoid cell line producing
RT   prolactin -- a cytogenetic characterization.";
RL   Cytotechnology 3:43-50(1990).
//
RX   PubMed=2836165; DOI=10.1210/endo-122-6-2508;
RA   DiMattia G.E., Gellersen B., Bohnet H.G., Friesen H.G.;
RT   "A human B-lymphoblastoid cell line produces prolactin.";
RL   Endocrinology 122:2508-2517(1988).
//
RX   PubMed=7579375; DOI=10.1182/blood.V86.10.4001.bloodjournal86104001;
RA   Pellat-Deceunynck C., Amiot M., Bataille R., Van Riet I., Van Camp B.,
RA   Omede P., Boccadoro M.;
RT   "Human myeloma cell lines as a tool for studying the biology of
RT   multiple myeloma: a reappraisal 18 years after.";
RL   Blood 86:4001-4002(1995).
//
RX   PubMed=8139288; DOI=10.1016/0145-2126(94)90118-x;
RA   Sato S., Honma Y., Hozumi M., Hayashi Y., Matsuo Y., Shibata K.,
RA   Omura S., Hino K.-i., Tomoyasu S., Tsuruoka N.;
RT   "Effects of herbimycin A and its derivatives on growth and
RT   differentiation of Ph1-positive acute lymphoid leukemia cell lines.";
RL   Leuk. Res. 18:221-228(1994).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=10516762; DOI=10.1038/sj.leu.2401510;
RA   Drexler H.G., Dirks W.G., MacLeod R.A.F.;
RT   "False human hematopoietic cell lines: cross-contaminations and
RT   misinterpretations.";
RL   Leukemia 13:1601-1607(1999).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29892436; DOI=10.1098/rsos.172472;
RA   Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M.,
RA   Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S.,
RA   Satoh M., Shimizu N., Kohara A.;
RT   "Screening for 15 pathogenic viruses in human cell lines registered at
RT   the JCRB Cell Bank: characterization of in vitro human cells by viral
RT   infection.";
RL   R. Soc. Open Sci. 5:172472-172472(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//